Benevolentai Bio Ltd. has discovered imidazopyridazine derivatives acting as high-affinity nerve growth factor receptor (NTRK1) and/or BDNF/NT-3 growth factor receptor (NTRK2) and/or NT-3 growth factor receptor (NTRK3) inhibitors reported to be useful for the treatment of atopic dermatitis.
Voronoi Inc. has identified heteroaryl compounds acting as HER2 (erbB2) and/or HER4 (erbB4) inhibitors reported to be useful for the treatment of cancer.
Nuvation Bio Inc. has disclosed drug conjugates comprising a nuclear receptor-targeting moiety covalently linked to a poly(ADP-ribose) polymerase 1 (PARP1) and/or PARP2 inhibitor though a linker. They are reported to be potentially useful for the treatment of cancer.
Merck KGaA and Cancer Research Technology Ltd. have synthesized 2,8-dihydropyrazolo[3,4-b]indoles acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, cardiovascular disorders and liver fibrosis.
Forendo Pharma Oy has presented aldo-keto reductase family 1 member C3 (AKR1C3) and/or prostaglandin F2-α synthase inhibitors reported to be useful for the treatment of acne, cancer, alopecia, obesity, chronic obstructive pulmonary disease, dysmenorrhea, endometriosis and polycystic ovary syndrome, among others.
Chengdu Easton Biopharmaceuticals Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) ligand binding moiety covalently bound to a bromodomain-containing protein 4 (BRD4; HUNK1)-targeting moiety through a linker.
Genescience Pharmaceuticals Co. Ltd. has divulged indoline-containing spiro derivatives acting as growth hormone secretagogue receptor (GHSR) agonists reported to be useful for the treatment of growth hormone deficiency.
RSS
